From the Journals

Smoking linked to increased psoriasis risk

Publish date: September 21, 2017
By
Richard Franki

 

FROM THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Current and former smokers were significantly more likely to have psoriasis than were nonsmokers in an analysis of the Korean National Health Insurance database.

Multivariate analyses produced adjusted incidence rates of 1.14 for current smokers (n = 132,566) and 1.11 for former smokers (n = 47,477), compared with nonsmokers (n = 320,435), indicating “that smoking status is an independent potential risk factor for psoriasis,” reported Eun Joo Lee, PhD, of the National Health Insurance Service in Wonjusi, South Korea, and associates (J Am Acad Dermatol. 2017;77[3]:573-5).

Psoriasis hazard ratios in smokers vs. nonsmokers
The data also “clearly showed that there is a positive correlation between the amount and/or duration of smoking and the occurrence of psoriasis,” they wrote, noting that “the association between duration of smoking and psoriasis has been controversial.” Subjects who smoked 30 years or more had the highest hazard rate for psoriasis, 1.32, as did those who smoked two or more packs of cigarettes per day, 1.25, the investigators said.

The study was supported by a grant from the National Research Foundation of Korea that was funded by the Korean government. The investigators did not declare any conflicts of interest.

Recommended Reading

Shingles vaccine deemed effective in people with autoimmune disease
MDedge Internal Medicine
What’s old is new in topical psoriasis therapy
MDedge Internal Medicine
Secukinumab beat etanercept in 52-week psoriasis quality of life analysis
MDedge Internal Medicine
How to get the most out of methotrexate for psoriasis
MDedge Internal Medicine
Some data support botulinum toxin for psoriasis and rosacea
MDedge Internal Medicine
Adalimumab outperforms methotrexate in treating severe pediatric plaque psoriasis
MDedge Internal Medicine
Infliximab biosimilar noninferior to originator in IBD – NOR-SWITCH
MDedge Internal Medicine
Pain often persists despite biologic treatment in PsA
MDedge Internal Medicine
First IL-23 blocker, guselkumab, earns FDA approval for psoriasis
MDedge Internal Medicine
FDA approves second adalimumab biosimilar for multiple conditions
MDedge Internal Medicine

Related Articles